A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Prostate Cancer | Cardiovascular DiseaseRADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
null
Participation Requirements
-
Sex:
MALE -
Eligible Ages:
45 and up
Participation Criteria
Inclusion Criteria:
1. A man with a diagnosis of prostate cancer that is either:
* new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
* treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
* to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Exclusion Criteria:
1. Patients will be excluded if they fulfill any of the following:
1. are unwilling to provide consent or
2. are \<45 years of age, or
3. prostate cancer was found incidentally following cystectomy for bladder cancer
2. Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
1. see a cardiologist every year, or
2. both take a statin and have systolic blood pressure ≤130mmHg
Study Location
Queen's University
Queen's UniversityKingston, Ontario
Canada
Contact Study Team
Dr. Robert Siemens, MD,FRCSC
Niagara Health, St. Catharines Site
Niagara Health, St. Catharines SiteNiagara, Ontario
Canada
Contact Study Team
Patrick Anderson
University Hospital of Montreal
University Hospital of MontrealMontreal, Quebec
Canada
Contact Study Team
Dr. Emmanuelle Duceppe, MD,FRCPC
Laval University
Laval UniversityQuebec City, Quebec
Canada
Contact Study Team
Dr. Vincent Fradet, MD,PhD,FRCSC
London Health Sciences, Victoria Hospital
London Health Sciences, Victoria HospitalLondon, Ontario
Canada
Contact Study Team
Melissa Huynh, B.Sc. (Hons), MD, FRCSC
Juravinski Cancer Centre
Juravinski Cancer CentreHamilton, Ontario
Canada
Contact Study Team
Dr. Jehonathan Pinthus, MD,FRCS(C),PhD
University Health Network, Princess Margaret Cancer Centre
University Health Network, Princess Margaret Cancer CentreToronto, Ontario
Canada
Contact Study Team
McGill University
McGill UniversityMontréal, Quebec
Canada
Contact Study Team
Negareh Mousavi, MD
Vancouver General Hospital
Vancouver General HospitalVancouver, British Columbia
Canada
Contact Study Team
Margot Davis, MD SM FRCPC
Ottawa Hospital Research Institute
Ottawa Hospital Research InstituteOttawa, Ontario
Canada
Contact Study Team
Dr. Luke Lavallee, MDCM,MSc,FRCSC
Grand River Hospital, Grand River Regional Cancer Centre
Grand River Hospital, Grand River Regional Cancer CentreKitchener, Ontario
Canada
Contact Study Team
Darin Gopaul, MD
Jewish General Hospital
Jewish General HospitalMontreal, Quebec
Canada
Contact Study Team
Dr. Tamim Niazi, MDCM
Centre Universitaire de Sherbrooke
Centre Universitaire de SherbrookeSherbrooke, Quebec
Canada
Contact Study Team
Robert Sabbagh, MSc, MD, FRCSC
St. Joseph's Healthcare
St. Joseph's HealthcareHamilton, Ontario
Canada
Contact Study Team
Dr. Bobby Shayegan, MD,FRCSC
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contact Study Team
Dr. Patrick Luke, MD,FRCSC
Hopital Maisonneuve-Rosemont
Hopital Maisonneuve-RosemontMontréal, Quebec
Canada
Contact Study Team
Nawar Hanna, MD, MSc
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contact Study Team
Dr. Laurence Klotz, MD,FRCS(C)
- Study Sponsored By
- McMaster University
- Participants Required
- More Information
- Study ID:
NCT03127631